mezigdomide   Click here for help

GtoPdb Ligand ID: 12718

Synonyms: CC-92480 | CC92480 | compound 4 [PMID: 32130004]
PDB Ligand
Compound class: Synthetic organic
Comment: Mezigdomide (CC-92480) is a modulator of the E3 ubiquitin ligase cereblon (CRBN) [1]. It is an immunomodulatory therapeutic candidate for the treatment of multiple myeloma (MM), with an emphasis for lenalidomide-resistant MM. CRBN-mediated degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) induces antitumor and immunomodulatory effects. Mezigdomide's degradion efficiency for IKZF3 is improved compared to pomalidomide and lenalidomide.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 105.98
Molecular weight 567.61
XLogP 0.26
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=CC(=C2CN([C@H]3CCC(=O)NC3=O)C(=O)C2=C1)OCC4=CC=C(C=C4)CN5CCN(CC5)C6=CC=C(C=C6F)C#N
Isomeric SMILES O=C1NC([C@H](CC1)N2CC=3C(OCC4=CC=C(CN5CCN(C6=CC=C(C#N)C=C6F)CC5)C=C4)=CC=CC3C2=O)=O
InChI InChI=1S/C32H30FN5O4/c33-26-16-23(17-34)8-9-27(26)37-14-12-36(13-15-37)18-21-4-6-22(7-5-21)20-42-29-3-1-2-24-25(29)19-38(32(24)41)28-10-11-30(39)35-31(28)40/h1-9,16,28H,10-15,18-20H2,(H,35,39,40)/t28-/m0/s1
InChI Key YTINZZFBHWSAGL-NDEPHWFRSA-N
No information available.
Summary of Clinical Use Click here for help
CC-92480 has advanced to clinical evaluations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03989414 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2 Interventional Celgene
NCT05519085 A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 3 Interventional Bristol-Myers Squibb
NCT05552976 A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Phase 3 Interventional Bristol-Myers Squibb